Switch theme
Sign up to access all valuation multiples
Viking Therapeutics Inc is a healthcare service provider. The company specializes in the area of biopharmaceutical development focused on metabolic and endocrine disorders. The company's clinical program pipeline consists of VK2809, VK5211, VK0214 products. VK2809 and VK0214 are orally available, tissue and receptor-subtype selective agonists of the thyroid hormone receptor beta. VK5211 is an orally available, non-steroidal selective androgen receptor modulator.
2012
36
LTM Revenue $0.6M
LTM EBITDA -$174M
$2.2B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Viking Therapeutics has a last 12-month revenue (LTM) of $0.6M and a last 12-month EBITDA of -$174M.
In the most recent fiscal year, Viking Therapeutics achieved revenue of n/a and an EBITDA of -$151M.
Viking Therapeutics expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Viking Therapeutics valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $0.6M | XXX | n/a | XXX | XXX | XXX |
| Gross Profit | $0.6M | XXX | n/a | XXX | XXX | XXX |
| Gross Margin | 100% | XXX | n/a | XXX | XXX | XXX |
| EBITDA | -$174M | XXX | -$151M | XXX | XXX | XXX |
| EBITDA Margin | -28623% | XXX | n/a | XXX | XXX | XXX |
| EBIT | -$190M | XXX | -$151M | XXX | XXX | XXX |
| EBIT Margin | -31162% | XXX | n/a | XXX | XXX | XXX |
| Net Profit | -$153M | XXX | -$110M | XXX | XXX | XXX |
| Net Margin | -25103% | XXX | n/a | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Viking Therapeutics's stock price is $27.
Viking Therapeutics has current market cap of $3.0B, and EV of $2.2B.
See Viking Therapeutics trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $2.2B | $3.0B | XXX | XXX | XXX | XXX | $-1.37 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Viking Therapeutics has market cap of $3.0B and EV of $2.2B.
Viking Therapeutics's trades at n/a EV/Revenue multiple, and -14.3x EV/EBITDA.
Equity research analysts estimate Viking Therapeutics's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Viking Therapeutics has a P/E ratio of -19.7x.
See valuation multiples for Viking Therapeutics and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $3.0B | XXX | $3.0B | XXX | XXX | XXX |
| EV (current) | $2.2B | XXX | $2.2B | XXX | XXX | XXX |
| EV/Revenue | 3547.0x | XXX | n/a | XXX | XXX | XXX |
| EV/EBITDA | -12.4x | XXX | -14.3x | XXX | XXX | XXX |
| EV/EBIT | -11.4x | XXX | -14.3x | XXX | XXX | XXX |
| EV/Gross Profit | 3547.0x | XXX | n/a | XXX | XXX | XXX |
| P/E | -19.7x | XXX | -27.4x | XXX | XXX | XXX |
| EV/FCF | -4.2x | XXX | -24.6x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialViking Therapeutics's last 12 month revenue growth is 480%
Viking Therapeutics's revenue per employee in the last FY averaged n/a, while opex per employee averaged $4.2M for the same period.
Viking Therapeutics's rule of 40 is unknown (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Viking Therapeutics's rule of X is -27422% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Viking Therapeutics and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 480% | XXX | n/a | XXX | XXX | XXX |
| EBITDA Margin | -28623% | XXX | n/a | XXX | XXX | XXX |
| EBITDA Growth | 41% | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | n/a | XXX | n/a | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | -27422% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $4.2M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Viking Therapeutics acquired XXX companies to date.
Last acquisition by Viking Therapeutics was XXXXXXXX, XXXXX XXXXX XXXXXX . Viking Therapeutics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Viking Therapeutics founded? | Viking Therapeutics was founded in 2012. |
| Where is Viking Therapeutics headquartered? | Viking Therapeutics is headquartered in United States of America. |
| How many employees does Viking Therapeutics have? | As of today, Viking Therapeutics has 36 employees. |
| Who is the CEO of Viking Therapeutics? | Viking Therapeutics's CEO is Dr. Brian Lian, PhD. |
| Is Viking Therapeutics publicy listed? | Yes, Viking Therapeutics is a public company listed on NAS. |
| What is the stock symbol of Viking Therapeutics? | Viking Therapeutics trades under VKTX ticker. |
| When did Viking Therapeutics go public? | Viking Therapeutics went public in 2015. |
| Who are competitors of Viking Therapeutics? | Similar companies to Viking Therapeutics include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Viking Therapeutics? | Viking Therapeutics's current market cap is $3.0B |
| What is the current revenue of Viking Therapeutics? | Viking Therapeutics's last 12 months revenue is $0.6M. |
| What is the current revenue growth of Viking Therapeutics? | Viking Therapeutics revenue growth (NTM/LTM) is 480%. |
| What is the current EV/Revenue multiple of Viking Therapeutics? | Current revenue multiple of Viking Therapeutics is 3547.0x. |
| Is Viking Therapeutics profitable? | Yes, Viking Therapeutics is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Viking Therapeutics? | Viking Therapeutics's last 12 months EBITDA is -$174M. |
| What is Viking Therapeutics's EBITDA margin? | Viking Therapeutics's last 12 months EBITDA margin is -28623%. |
| What is the current EV/EBITDA multiple of Viking Therapeutics? | Current EBITDA multiple of Viking Therapeutics is -12.4x. |
| What is the current FCF of Viking Therapeutics? | Viking Therapeutics's last 12 months FCF is -$519M. |
| What is Viking Therapeutics's FCF margin? | Viking Therapeutics's last 12 months FCF margin is -85310%. |
| What is the current EV/FCF multiple of Viking Therapeutics? | Current FCF multiple of Viking Therapeutics is -4.2x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
